Companies
- Companies
- Company details
Acorda Therapeutics
Out-licensing
Development of Remyelinating Monoclonal Antibodies for the Treatment of Multiple Sclerosis More
Phase III Clinical Development of Fampridine-SR for the Treatment of Multiple Sclerosis More
Plasticity and Regeneration: The Efficacy of Chondroitinase in Spinal Cord Injury More
Towards the Development of Neuregulins as Novel Therapeutics for the Treatment of Multiple Sclerosis
Towards the Development of Neuregulins as Novel Therapeutics for the Treatment of Multiple Sclerosis More
R&D
To view this information, you must subscribe to Pharmalicensing Intelligence.
Partnerships
To view this information, you must subscribe to Pharmalicensing Intelligence.
Deals
To view this information, you must subscribe to Pharmalicensing Intelligence.
Senior management
To view this information, you must subscribe to Pharmalicensing Intelligence.
Board of directors
To view this information, you must subscribe to Pharmalicensing Intelligence.
Related Reports
Market Research Reports provided by reports.iptechex.com
Sep 2010 - 23 pages - $99
Jul 2010 - 25 pages - $125
Nov 2010 - 40 pages - $500
Mar 2011 - 43 pages - $125
Jun 2011 - 53 pages - $125
Nov 2007 - 47 pages - $495
Jan 2010 - $75
Sep 2011 - 25 pages - $99
Nov 2010 - 103 pages - $600
May 2011 - 42 pages - $125
Contact details
Gerard Cignarella
Head office
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us